Does the media favor CPRX or ELAN?

In the previous week, Elanco Animal Health had 8 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 9 mentions for Elanco Animal Health and 1 mentions for Catalyst Pharmaceuticals. Elanco Animal Health's average media sentiment score of 0.72 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elanco Animal Health 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or CPRX?

In the previous week, Axsome Therapeutics had 11 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 12 mentions for Axsome Therapeutics and 1 mentions for Catalyst Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 0.77 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CPRX or ABVX?

In the previous week, Abivax had 12 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 13 mentions for Abivax and 1 mentions for Catalyst Pharmaceuticals. Abivax's average media sentiment score of 1.41 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SMMT or CPRX?

In the previous week, Summit Therapeutics had 12 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 13 mentions for Summit Therapeutics and 1 mentions for Catalyst Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.35 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Catalyst Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Catalyst Pharmaceuticals (CPRX) Competitors

$31.49 0.00 (0.00%)

As of 07/16/2026

Compare

CPRX vs. ELAN, AXSM, ARWR, ABVX, and SMMT

Should you buy Catalyst Pharmaceuticals stock or one of its competitors? MarketBeat compares Catalyst Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Catalyst Pharmaceuticals include Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), Arrowhead Pharmaceuticals (ARWR), Abivax (ABVX), and Summit Therapeutics (SMMT).

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Elanco Animal Health (NYSE:ELAN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

In the previous week, Elanco Animal Health had 8 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 9 mentions for Elanco Animal Health and 1 mentions for Catalyst Pharmaceuticals. Elanco Animal Health's average media sentiment score of 0.72 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elanco Animal Health	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Catalyst Pharmaceuticals currently has a consensus price target of $32.00, indicating a potential upside of 1.62%. Elanco Animal Health has a consensus price target of $28.73, indicating a potential upside of 11.85%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, analysts clearly believe Elanco Animal Health is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Catalyst Pharmaceuticals has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10
Elanco Animal Health	$4.72B	2.72	-$232M	-$0.50	N/A

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 1.1% of Elanco Animal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Elanco Animal Health's net margin of -4.95%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Elanco Animal Health	-4.95%	7.42%	3.66%

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market.

Summary

Elanco Animal Health beats Catalyst Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.01	-$183.17M	-$3.73	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

Axsome Therapeutics presently has a consensus price target of $261.29, suggesting a potential upside of 23.81%. Catalyst Pharmaceuticals has a consensus price target of $32.00, suggesting a potential upside of 1.62%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	2 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.91
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

In the previous week, Axsome Therapeutics had 11 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 12 mentions for Axsome Therapeutics and 1 mentions for Catalyst Pharmaceuticals. Axsome Therapeutics' average media sentiment score of 0.77 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Axsome Therapeutics' net margin of -26.59%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Axsome Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

Summary

Axsome Therapeutics beats Catalyst Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Catalyst Pharmaceuticals presently has a consensus target price of $32.00, indicating a potential upside of 1.62%. Arrowhead Pharmaceuticals has a consensus target price of $96.92, indicating a potential upside of 12.68%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.62

Catalyst Pharmaceuticals has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10
Arrowhead Pharmaceuticals	$829.45M	14.61	-$1.63M	-$2.15	N/A

In the previous week, Arrowhead Pharmaceuticals had 20 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 21 mentions for Arrowhead Pharmaceuticals and 1 mentions for Catalyst Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.07 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Summary

Catalyst Pharmaceuticals beats Arrowhead Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Abivax?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

In the previous week, Abivax had 12 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 13 mentions for Abivax and 1 mentions for Catalyst Pharmaceuticals. Abivax's average media sentiment score of 1.41 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Catalyst Pharmaceuticals has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Catalyst Pharmaceuticals has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Abivax has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

Catalyst Pharmaceuticals currently has a consensus price target of $32.00, indicating a potential upside of 1.62%. Abivax has a consensus price target of $156.50, indicating a potential upside of 25.42%. Given Abivax's stronger consensus rating and higher probable upside, analysts plainly believe Abivax is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Abivax's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Abivax	N/A	-99.02%	-70.26%

Summary

Catalyst Pharmaceuticals beats Abivax on 9 of the 15 factors compared between the two stocks.

How does Catalyst Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Summit Therapeutics' net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Summit Therapeutics currently has a consensus target price of $26.15, suggesting a potential upside of 100.42%. Catalyst Pharmaceuticals has a consensus target price of $32.00, suggesting a potential upside of 1.62%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

In the previous week, Summit Therapeutics had 12 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 13 mentions for Summit Therapeutics and 1 mentions for Catalyst Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.35 beat Catalyst Pharmaceuticals' score of 0.00 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Catalyst Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summit Therapeutics has a beta of -1.23, suggesting that its stock price is 223% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats Summit Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Catalyst Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPRX vs. The Competition

Export

Metric	Catalyst Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.86B	$11.48B	$6.81B	$12.68B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	18.10	793.98	281.02	25.13
Price / Sales	6.46	753.17	590.80	93.66
Price / Cash	10.77	14.82	28.64	34.82
Price / Book	4.06	10.39	11.02	6.21
Net Income	$214.33M	$2.80B	$3.48B	$347.49M
7 Day Performance	N/A	0.30%	0.56%	0.89%
1 Month Performance	0.13%	-3.70%	-4.14%	-3.60%
1 Year Performance	49.10%	156.59%	63.23%	20.46%

Catalyst Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPRX Catalyst Pharmaceuticals	3.4074 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80	Positive News Upcoming Earnings
ELAN Elanco Animal Health	3.1976 of 5 stars	$25.48 +2.3%	$28.73 +12.7%	+91.5%	$12.44B	$4.72B	N/A	9,400	Positive News Upcoming Earnings Analyst Upgrade
AXSM Axsome Therapeutics	3.6061 of 5 stars	$238.37 -1.1%	$261.48 +9.7%	+111.6%	$12.40B	$638.50M	N/A	380	Upcoming Earnings Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.2275 of 5 stars	$85.53 -0.1%	$95.08 +11.2%	+431.4%	$12.06B	$829.45M	N/A	400	Positive News Upcoming Earnings
ABVX Abivax	3.9428 of 5 stars	$128.00 +1.8%	$156.50 +22.3%	+73.6%	$10.97B	N/A	N/A	61	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CPRX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Catalyst Pharmaceuticals (CPRX) Competitors

CPRX vs. ELAN, AXSM, ARWR, ABVX, and SMMT

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Summary

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Catalyst Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Summary

How does Catalyst Pharmaceuticals compare to Abivax?

Summary

How does Catalyst Pharmaceuticals compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPRX vs. The Competition

Catalyst Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Catalyst Pharmaceuticals (CPRX) Competitors

CPRX vs. ELAN, AXSM, ARWR, ABVX, and SMMT

How does Catalyst Pharmaceuticals compare to Elanco Animal Health?

Does the media favor CPRX or ELAN?

Do analysts rate CPRX or ELAN?

Which has preferable earnings & valuation, CPRX or ELAN?

Do insiders & institutionals have more ownership in CPRX or ELAN?

Is CPRX or ELAN more profitable?

Which has more risk & volatility, CPRX or ELAN?

Summary

How does Catalyst Pharmaceuticals compare to Axsome Therapeutics?

Which has higher valuation and earnings, AXSM or CPRX?

Do analysts rate AXSM or CPRX?

Does the media prefer AXSM or CPRX?

Do institutionals & insiders have more ownership in AXSM or CPRX?

Is AXSM or CPRX more profitable?

Which has more risk and volatility, AXSM or CPRX?

Summary

How does Catalyst Pharmaceuticals compare to Arrowhead Pharmaceuticals?

Do analysts recommend CPRX or ARWR?

Which has stronger earnings and valuation, CPRX or ARWR?

Does the media favor CPRX or ARWR?

Do insiders and institutionals believe in CPRX or ARWR?

Which has more risk & volatility, CPRX or ARWR?

Is CPRX or ARWR more profitable?

Summary

How does Catalyst Pharmaceuticals compare to Abivax?

Does the media favor CPRX or ABVX?

Do insiders & institutionals believe in CPRX or ABVX?

Which has stronger valuation & earnings, CPRX or ABVX?

Which has more risk & volatility, CPRX or ABVX?

Do analysts rate CPRX or ABVX?

Is CPRX or ABVX more profitable?

Summary

How does Catalyst Pharmaceuticals compare to Summit Therapeutics?

Do institutionals and insiders hold more shares of SMMT or CPRX?

Is SMMT or CPRX more profitable?

Do analysts recommend SMMT or CPRX?

Which has stronger earnings & valuation, SMMT or CPRX?

Does the media prefer SMMT or CPRX?

Which has more volatility and risk, SMMT or CPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPRX vs. The Competition

Catalyst Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools